[1]
Vill K., Kölbel H., Schwartz O., et al.: One Year of Newborn Screening for
SMA - Results of a German Pilot Project. J Neuromuscul Dis. 2019; 6:
503-515. doi:10.3233/JND-190428
[2]
Jedrzejowska M., Milewski M., Zimowski J., et al.: Incidence of
Spinal Muscular Atrophy in Poland – More Frequent than Predicted?
Neuroepidemiology. 2010; 34: 152-157. doi:10.1159/000275492
[3]
Lusakowska A., Jedrzejowska M., Kaminska A., et al.: Observation of the
natural course of type 3 spinal muscular atrophy: data from the polish
registry of spinal muscular atrophy. Orphanet J Rare Dis 2021;16 :1-9.
doi:10.1186/S13023-021-01771-Y
[4]
Jędrzejowska M.: Advances in Newborn Screening and Presymptomatic
Diagnosis of Spinal Muscular Atrophy. Degener Neurol Neuromuscul Dis.
2020; 10: 39-47. doi:10.2147/DNND.S246907
[5]
Lefebvre S., Bürglen L., Reboullet S., et al.: Identification and characterization
of a spinal muscular atrophy-determining gene. Cell. 1995; 80: 155-165.
doi:10.1016/0092-8674(95)90460-3
[6]
Jedrzejowska M., Borkowska J., Zimowski J., et al.: Unaffected patients
with a homozygous absence of the SMN1 gene. Eur J Hum Genet. 2008;
16: 930-934. doi:10.1038/EJHG.2008.41
[7]
Wirth B., Brichta L., Schrank B., et al.: Mildly affected patients with spinal
muscular atrophy are partially protected by an increased SMN2 copy
number. Hum Genet. 2006; 119: 422-428. doi:10.1007/S00439-006-
0156-7
[8]
Russman B. S.: Spinal muscular atrophy: clinical classification
and disease heterogeneity. J Child Neurol. 2007; 22: 946-951.
doi:10.1177/0883073807305673
[9]
Zerres K., Davies K.E.: 59th ENMC International Workshop: Spinal Muscular
Atrophies: recent progress and revised diagnostic criteria 17-19 April
1998, Soestduinen, The Netherlands. Neuromuscul Disord. 1999; 9: 272-
278. doi:10.1016/S0960-8966(99)00016-4
[10]
Wijngaarde C.A., Veldhoen E.S., van Eijk R., et al.: Natural history of
lung function in spinal muscular atrophy. Orphanet J Rare Dis. 2020; 15.
doi:10.1186/S13023-020-01367-Y
[11]
Dubowitz V.: Very severe spinal muscular atrophy (SMA type 0): an
expanding clinical phenotype. Eur J Paediatr Neurol. 1999; 3: 49-51.
doi:10.1053/ejpn.1999.0181
[12]
Kolb S.J., Coffey C.S., Yankey J.W., et al.: Natural history of infantile-onset
spinal muscular atrophy. Ann Neurol. 2017; 82: 883-891. doi:10.1002/
ANA.25101
[13]
de Sanctis R., Pane M., Coratti G., et al.: Clinical phenotypes and
trajectories of disease progression in type 1 spinal muscular atrophy.
Neuromuscul Disord. 2018; 28: 24-28. doi:10.1016/J.NMD.2017.09.015
[14]
Mercuri E., Lucibello S., Perulli M., et al.: Longitudinal natural history of
type I spinal muscular atrophy: a critical review. Orphanet J Rare Dis
2020 15:1. 2020; 15: 1-7. doi:10.1186/S13023-020-01356-1
[15]
Finkel R.S., McDermott M.P., Kaufmann P., et al.: Observational study
of spinal muscular atrophy type I and implications for clinical trials.
Neurology. 2014; 83: 810-817. doi:10.1212/WNL.0000000000000741
[16]
Kotulska K., Chmielewski D., Mazurkiewicz-Bełdzińska M., et al.: Safety,
tolerability, and efficacy of a widely available nusinersen program for
Polish children with Spinal Muscular Atrophy. Eur J Paediatr Neurol.
2022; 39: 103-109. doi:10.1016/J.EJPN.2022.06.001
[17]
Finkel R.S., Chiriboga C.A., Vajsar J., et al.: Treatment of infantile-onset
spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-
escalation study. Lancet. 2016; 388: 3017-3026. doi:10.1016/S0140-
6736(16)31408-8
[18]
Finkel R.S., Mercuri E., Darras B.T., et al.: Nusinersen versus Sham
Control in Infantile-Onset Spinal Muscular Atrophy. N Engl J Med. 2017;
377: 1723-1732. doi:10.1056/nejmoa1702752
[19]
Jędrzejowska M., Kostera-Pruszczyk A.: Rdzeniowy zanik mięśni – nowe
terapie, nowe wyzwania. Neurol Dziec. 2017; 26: 11-17. doi:10.20966/
CHN.2017.52.400
[20]
Chabanon A., Seferian A.M., Daron A., et al.: Prospective and longitudinal
natural history study of patients with Type 2 and 3 spinal muscular
atrophy: Baseline data NatHis-SMA study. PLoS One. 2018; 13.
doi:10.1371/JOURNAL.PONE.0201004
[21]
Finkel R.S., Weiner D.J., Mayer O.H., et al.: Respiratory muscle function in
infants with spinal muscular atrophy type I. Pediatr Pulmonol. 2014; 49:
1234-1242. doi:10.1002/PPUL.22997
[22]
Finkel R.S., McDermott M.P., Kaufmann P., et al.: Observational study
of spinal muscular atrophy type I and implications for clinical trials.
Neurology. 2014; 83: 810-817. doi:10.1212/WNL.0000000000000741
[23]
Coratti G., Messina S., Lucibello S., et al.: Clinical Variability in Spinal
Muscular Atrophy Type III. Ann Neurol. 2020; 88: 1109-1117.
doi:10.1002/ANA.25900
[24]
Zerres K., Rudnik-Schöneborn S., Forrest E., et al.: A collaborative study
on the natural history of childhood and juvenile onset proximal spinal
muscular atrophy (type II and III SMA): 569 patients. J Neurol Sci. 1997;
146: 67-72. doi:10.1016/S0022-510X(96)00284-5
[25]
Piepers S., van den Berg L.H., Brugman F., et al.: A natural history study of
late onset spinal muscular atrophy types 3b and 4. J Neurol. 2008; 255:
1400-1404. doi:10.1007/S00415-008-0929-0
[26]
Darras B.T., Farrar M.A., Mercuri E., et al.: An Integrated Safety Analysis
of Infants and Children with Symptomatic Spinal Muscular Atrophy
(SMA) Treated with Nusinersen in Seven Clinical Trials. CNS Drugs.
2019; 33: 919-932. doi:10.1007/S40263-019-00656-W
[27]
Pechmann A., Langer T., Schorling D., et al.: Evaluation of Children with
SMA Type 1 Under Treatment with Nusinersen within the Expanded
Access Program in Germany. J Neuromuscul Dis. 2018; 5: 135-143.
doi:10.3233/JND-180315
[28]
Baranello G., Darras B.T., Day J.W., et al.: Risdiplam in Type 1 Spinal
Muscular Atrophy. N Engl J Med. 2021; 384: 915-923. doi:10.1056/
NEJMoa2009965
[29]
Darras B.T., Masson R., Mazurkiewicz-Bełdzińska M., et al.: Risdiplam-
Treated Infants with Type 1 Spinal Muscular Atrophy versus
Historical Controls. N Engl J Med. 2021; 385: 427-435. doi:10.1056/
NEJMOA2102047
[30]
Al-Zaidy S., Simon Pickard A., Kotha K., et al.: Health outcomes in spinal
muscular atrophy type 1 following AVXS-101 gene replacement therapy.
Pediatr Pulmonol. 2019; 54: 179-185. doi:10.1002/ppul.24203
[31]
Mendell J.R., Al-Zaidy S., Shell R., et al.: Single-Dose Gene-Replacement
Therapy for Spinal Muscular Atrophy. N Engl J Med. 2017; 377: 1713-
1722. doi:10.1056/NEJMOA1706198
[32]
Al-Zaidy S.A., Kolb S.J., Lowes L., et al.: AVXS-101 (Onasemnogene
Abeparvovec) for SMA1: Comparative Study with a Prospective Natural
History Cohort. J Neuromuscul Dis. 2019; 6: 307-317. doi:10.3233/JND-
190403
[33]
Mercuri E., Pera M.C., Scoto M., et al.: Spinal muscular atrophy —
insights and challenges in the treatment era. Nature Reviews Neurology
2020 16:12. 2020; 16: 706-715. doi:10.1038/s41582-020-00413-4
[34]
Finkel R.S., Mercuri E., Meyer O.H., et al.: Diagnosis and management
of spinal muscular atrophy: Part 2: Pulmonary and acute care;
medications, supplements and immunizations; other organ systems;
and ethics. Neuromuscul Disord. 2018; 28: 197-207. doi:10.1016/J.
NMD.2017.11.004
[35]
Mercuri E., Finkel R.S., Muntoni F., et al.: Diagnosis and management
of spinal muscular atrophy: Part 1: Recommendations for diagnosis,
rehabilitation, orthopedic and nutritional care. Neuromuscul Disord.
2018; 28: 103-115. doi:10.1016/J.NMD.2017.11.005
[36]
Kostera Pruszczyk A.: How real world data guides SMA management.
Abstracts of the 8th Congress of the European Academy of Neurology,
European Journal of Neurology, Volume 29, Supplement 1, June
2022 Address: https://www.ean.org/fileadmin/user_upload/ean/
congress-2022/EAN2022AbstractBook.pdf
[37]
Calucho M., Bernal S., Alías L., et al.: Correlation between SMA type
and SMN2 copy number revisited: An analysis of 625 unrelated Spanish
patients and a compilation of 2834 reported cases. Neuromuscul Disord.
2018; 28: 208-215. doi:10.1016/J.NMD.2018.01.003
[38]
Kostera-Pruszczyk A., Napiórkowski Ł., Szymańska K., et al.: Spinal
muscular atrophy: epidemiology and health burden in children —
a Polish national healthcare database perspective before introduction
of SMA-specific treatment. Neurol Neurochirur Pol. 2021; 55: 479-484.
doi:10.5603/PJNNS.A2021.0074
[39]
Wirth B., Herz M., Wetter A., et al.: Quantitative Analysis of Survival
Motor Neuron Copies: Identification of Subtle SMN1 Mutations in
Patients with Spinal Muscular Atrophy, Genotype-Phenotype Correlation,
and Implications for Genetic Counseling. Am J Hum Genet. 1999; 64:
1340-1356. doi:10.1086/302369
[40]
Wijngaarde C.A., Brink R.C., de Kort F.A.S., et al.: Natural course of
scoliosis and lifetime risk of scoliosis surgery in spinal muscular atrophy.
Neurology. 2019; 93: 149-158. doi:10.1212/WNL.0000000000007742
Scholar Google
PubMed